$KMB

Kimberly-Clark seeks EU approval for its $40bn acquisition of Kenvue, aiming to create a consumer health and personal care giant with $32bn annual revenue. The deal, announced last November, targets $2.1bn in annual cost savings. EU regulators will assess competition concerns, with a decision pending. The acquisition would expand Kimberly-Clark's portfolio to include brands like Tylenol, Listerine, and Neutrogena.

Kimberly-Clark (KMB) has requested EU approval for its $40 billion acquisition of Kenvue, the maker of Tylenol. The deal, announced in November 2023, is expected to close in the second half of 2026. Kimberly-Clark anticipates $2.1 billion in annual cost savings and $32 billion in combined annual revenues, including Kenvue's brands like Listerine, Aveeno, and Neutrogena.

Andrex, a Kimberly-Clark brand, launched Andrex Skin Protect in the UK, its biggest innovation in over 20 years. The product, developed over 3 years with consumer testing, focuses on skin care. The company also introduced Andrex Protect & Care wet wipes in the UK and Ireland, expanding its intimate care portfolio.

Kimberly-Clark (KMB) seeks EU antitrust approval for its $49B acquisition of Kenvue (KVUE), with a provisional deadline set for Sept. 29. The deal, approved by shareholders in January, still faces regulatory reviews in several jurisdictions, including China's Phase 2 examination. The companies aim to complete the transaction in Q4 2026, subject to approvals.

Kimberly-Clark (KMB) seeks European antitrust approval for its $40B acquisition of Kenvue (KVUE), with a decision deadline set for September 29. The company's dividend yield is 4.59%, but its high payout ratio raises sustainability concerns. KMB's stock is modestly undervalued with a GF Value™ of $123.73 vs. the current price of $110.34. The company has a GF Score™ of 72, reflecting strong profitability and valuation but weaker growth prospects.

Kimberly-Clark plans to use hesperaloe, a desert succulent, as an alternative fiber source for its tissue and toilet paper products, aiming to reduce reliance on wood pulp. The company has built a facility in Arizona to explore this rapidly renewable resource, having tested 70 alternatives. This initiative is supported by environmental groups seeking to reduce deforestation.

Kimberly-Clark launched Kleenex Beauty Tissues in the UK, targeting beauty and personal care routines. Two variants cater to different skin types, with one absorbing oil and the other maintaining moisture. The product will be available in at-home and portable formats from September 1, marking the company's biggest innovation in 30 years.

New Zealand approved Kimberly-Clark's acquisition of Kenvue, requiring the divestment of Kenvue's feminine hygiene brands (Carefree, Stayfree) in NZ and Australia. The move aims to prevent market concentration. Kimberly-Clark must sell the unit to an approved buyer to complete the deal.

Analysts updated recommendations for multiple companies. Kimberly-Clark (KMB) was downgraded to underperform with a higher price target. Palantir (PLTR) was upgraded to buy. Snap (SNAP) was upgraded to buy with a slightly lower target. Accenture (ACN) and others saw price target increases.

Kimberly-Clark (KMB) received approval from New Zealand’s Commerce Commission to acquire Kenvue, contingent on divesting Kenvue’s feminine hygiene business in NZ and Australia. The regulator cited competition concerns, requiring the sale to an approved buyer to maintain market competition. The deal is part of Kimberly-Clark’s global acquisition of Kenvue.